BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 25, 2004
 |  BioCentury  |  Product Development

Roche's HDL play

Roche's deal for JTT-705 puts the company into the increasingly hot HDL cholesterol space with a cholesteryl ester transfer protein (CETP) inhibitor. CETP inhibitors increase HDL levels and are expected to be used to treat dyslipidemia, especially in metabolic syndromes. Pfizer Inc. and Avant Immunotherapeutics Inc. are developing products against the same target.

Last week, Roche (SWX:

ROCZ, Basel, Switzerland) in-licensed exclusive worldwide rights to the compound, excluding Japan and Korea, from Japan Tobacco Inc. (Tokyo, Japan) (see B4).JTT-705, which is in Phase II...

Read the full 429 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >